Healthy Clinical Trial
Official title:
The Effect of the Levonorgestrel-Releasing Intrauterine System and the Copper-Intrauterine Device (TCu 380A) on Subendometrial Microvascularization and Uterine Artery Blood Flow.
The aim of this study was to evaluate the effect of the LNG-IUS and TCU 380A users on the sub-endometrial vascularization and the uterine artery blood flow using power Doppler analysis and ultrasonography pulsed color Doppler during the precise mid-luteal phase.
Design We will perform a prospective (quasi-experimental) clinical trial.
Patients/Methodology We prospectively will enrolled consecutive patients who wants to use
IUD (LNG-IUS or TCU 380A). We will evaluate the sub-endometrial blood flow using power
Doppler analysis, uterine artery blood flow using pulsatility and resistance index and
endometrial thickness before IUD insertion and three months later.
The inclusion criteria are: 1. regularly menstruating women (menstrual cycle varying between
24-35 days); 2. Normal serum TSH, FSH and prolactin levels (as measured on day-3) and with
less than 40 years. Contraceptive pills or any kind of hormonal medication had not been
taken for (at least) 3 months prior to the study and any intrauterine device had necessarily
been removed at least 3 months earlier. Patients will be allowed to not use non-steroidal
anti-inflammatory drugs (NSAID) within 24 h prior to any examination.
The exclusion criteria are pregnancy, acute or chronic pelvic inflammatory disease,
menorrhagia for unknown reason, copper allergy, cervicitis, dysplasia in the cervix or
genital tumor. All patients underwent a gynecological examination and had a Papanicolaou
smear taken during the previous 12 months.
All patients will be daily examined with US after the eighth day of the cycle, and
follicular development will be observed to confirm ovulation; they are then examined in the
mid-luteal phase, 6-9 days after ovulation, to obtain the power Doppler energy (PDE)
measurement, pulsatility index (PI), resistance index (RI) and endometrial thickness (ET) by
ultrasound (US) scans. The study was approved by the Ethical Committee of Hospital de
Clinicas de Porto Alegre, IRB equivalent (# 02-127) and informed consent was obtained from
all patients.
Patients will be allocated into 2 groups according to the IUD: LNG-IUS (group A) or TCu 380A
(group B).
Three months after the LNG-IUS (group A) or TCu 380A (group B) insertion, also in the
mid-luteal phase (6-9 days after ovulation, confirmed by US), all subjects repeated the same
study protocol.
The sonographic equipment that will be used consisted of a SONOACE 9900 (Medison SA –
Korea). The PDE, PI and RI will be performed on a transvaginal route. The settings for Power
Doppler sonography are standardized for the highest sensitivity in the absence of apparent
noise using a high pass filter at 50 Hz, pulsed repetition frequency at 750 Hz, and moderate
long persistence. The lowest possible measurable velocity was below 5 cm/s. The same
investigator, using the same equipment and parameters will performe the sonography
assessments so as to eliminate any interobserver variation. All exams were carried out
between 08:00 and 10:00 a.m. in order to avoid interference of the circadian rhythm (10).
Power Doppler energy is classified into 5 categories according to the sub-endometrial signal
area percentage: I (<10%), II (10-25%), III (25-50%), IV (50-75%) and V (>75%).
Statistics Student t test is used for comparing age and body mass index (BMI). The
Wilcoxon-Mann-Whitney (WMW) test is used to compare skewed data (PI, RI and ET), whereas the
Chi-Square test and Fisher’s exact test are used for categorical data (PDE).
We will use multiple logistic regression model to examine the association of the outcome (PI
variability, before and after IUD insertion), categorized in percentile 50 and IUD (LNG-IUS
or TCu 380A), age (years), and parity (0,1 or >1) the independent variables. P-value < 0.05
was considered statistically significant. The power calculation before this study protocol
required the inclusion of 19 patients for a Pß=80%.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |